This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Savient Pharmaceuticals And Jim Belushi Launch "Check Out Your Gout" Educational Campaign

EAST BRUNSWICK, N.J., Nov. 7, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) and Jim Belushi today announced the launch of a new educational campaign, "Check Out Your Gout," to raise awareness about gout and a severe form of the condition known as refractory chronic gout, or RCG. As an actor, singer and performer, Belushi's roles range from dramatic to light-hearted, but when it comes to his gout – he is nothing but serious. The "Check Out Your Gout" campaign aims to encourage people to get serious about gout and take action to learn more about the condition. Launched from Chicago, Belushi's hometown and location of the 2011 Annual Meeting of the American College of Rheumatology taking place this week, the campaign will feature broadcast and online videos, as well as an educational website, CheckOutYourGout.com.

To view the multimedia content associated with this release, please click:   http://www.multivu.com/players/English/51932-savient-pharmaceuticals-and-jim-belushi-launch-gout-awareness-campaign/

(Photo: http://photos.prnewswire.com/prnh/20111107/MM00878)

Gout is a debilitating form of arthritis affecting approximately eight million Americans. Triggered by high levels of uric acid in the blood, gout causes pain and swelling in the joints and can result in deposits of uric acid crystals under the skin, called tophi. RCG occurs when uric acid levels remain high, and signs and symptoms persist despite available conventional therapies. RCG signs and symptoms may be debilitating due to the frequency and severity of episodes, the recurrent painful gout attacks and the disfigurement associated with the condition.

"When I first developed gout, I didn't want to do anything about it. I thought I could tough it out; but when the pain became too unbearable for me to perform on stage, I saw a rheumatologist and got my gout under control," said Belushi. "I am taking part in the 'Check Out Your Gout' campaign to let people know that gout is a very painful condition that should be taken seriously, and to tell those who are or may be affected by gout or RCG to check it out and work with a doctor to identify the best management plan."

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,976.31 +263.65 1.49%
S&P 500 2,086.24 +25.22 1.22%
NASDAQ 4,947.4410 +56.2220 1.15%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs